A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
To investigate cardiac impairment, the investigators will perform transthoracic echocardiography in all enrolled pregnant women and infants, with a focus on right-sided cardiac anatomy and function, including pulmonary artery pressures, right ventricular thickness, right ventricular systolic performance, and indices of pulmonary vascular load.
To investigate the effects of hypobaric hypoxia on fetal growth, the investigators will measure intrauterine and post-delivery growth parameters, assess placental weight and histologic features, and correlate these findings with maternal oxygenation status and altitude exposure.
To assess nitric oxide production and consumption, the investigators will quantify nitric oxide-related metabolites (NO metabolomics) in maternal blood, umbilical cord blood, and placental tissue in both cohorts, and correlate these biomarkers with pulmonary arterial pressures, and right ventricular function. The investigators will also assess flow-mediated dilation in the high altitude cohort and relate these measures of endothelial function to pulmonary vascular and obstetric outcomes.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Lorenzo Berra, MD
- Phone Number: 617-726-3030
- Email: lberra@mgh.harvard.edu
Study Contact Backup
- Name: Andrea Bolchini, MD
- Phone Number: 617-216-5124
- Email: abolchini@mgh.harvard.edu
Study Locations
-
-
-
La Paz, Bolivia
- Completed
- Hospital De La Meujer
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Lorenzo Berra, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- women delivering at participating hospitals at more than 3500 meters or women delivering at participating hospitals at sea level
- signed informed consent
Exclusion Criteria:
- preexisting cardiopulmonary pathologies (CHD, COPD, CKD, NYHA > III)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Healthy pregnant women residing at high altitude
Women with uncomplicated pregnancy.
|
|
Healthy pregnant women residing at sea level
Women with uncomplicated pregnancy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary artery pressures
Time Frame: Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks)
|
Measurement will be performed by transthoracic echocardiography.
|
Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks)
|
|
Echographic estimate of fetal weight
Time Frame: Late pregnancy (35 ± 4 weeks gestation)
|
Late pregnancy (35 ± 4 weeks gestation)
|
|
|
Nitric oxide metabolites
Time Frame: Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks) for maternal samples, at delivery (neonatal samples)
|
Measurement will be performed with a chemiluminescence assay.
|
Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks) for maternal samples, at delivery (neonatal samples)
|
|
RV remodeling echocardiography parameters
Time Frame: Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks)
|
Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks)
|
|
|
Weight at birth
Time Frame: At delivery
|
At delivery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lorenzo Berra, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Female Urogenital Diseases and Pregnancy Complications
- Pregnancy Complications
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Fetal Diseases
- Growth Disorders
- Hypertension, Pulmonary
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Pulmonary Arterial Hypertension
- Fetal Growth Retardation
- Toxemia
Other Study ID Numbers
Other Study ID Numbers
- PregHigh
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.